SN
BMY.RT

Sittner & Nelson’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Sittner & Nelson’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-399
Closed – – 463
2020
Q4 		$0 Buy
+399
New +$850 ﹤0.01% 430

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Sittner & Nelson's BMY.RT Position: Q1 2021 in Review

Sittner & Nelson sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 399 shares.

Sittner & Nelson first reported a position in BMY.RT in Q4 2020 and held it in 1 quarter. The position peaked at $0 in Q4 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Sittner & Nelson reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Sittner & Nelson sold 399 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021.
  • Sittner & Nelson first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2020 and held it in 1 quarter.
  • Sittner & Nelson's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $0 in Q4 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Sittner & Nelson's 13F filing for Q1 2021, filed 6 May 2021.